Singapore markets close in 7 hours 47 minutes
  • Straits Times Index

    3,378.29
    0.00 (0.00%)
     
  • Nikkei

    27,452.60
    +19.20 (+0.07%)
     
  • Hang Seng

    22,069.73
    -619.17 (-2.73%)
     
  • FTSE 100

    7,784.87
    +19.72 (+0.25%)
     
  • BTC-USD

    22,837.24
    -901.05 (-3.80%)
     
  • CMC Crypto 200

    517.77
    -20.10 (-3.74%)
     
  • S&P 500

    4,017.77
    -52.79 (-1.30%)
     
  • Dow

    33,717.09
    -260.99 (-0.77%)
     
  • Nasdaq

    11,393.81
    -227.90 (-1.96%)
     
  • Gold

    1,938.60
    -0.60 (-0.03%)
     
  • Crude Oil

    78.01
    +0.11 (+0.14%)
     
  • 10-Yr Bond

    3.5510
    +0.0330 (+0.94%)
     
  • FTSE Bursa Malaysia

    1,499.39
    +1.84 (+0.12%)
     
  • Jakarta Composite Index

    6,872.48
    -26.50 (-0.38%)
     
  • PSE Index

    6,970.97
    -81.19 (-1.15%)
     

Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference

CHICAGO, September 01, 2022--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference, occurring October 3-4, 2022.

The presentation will be available for on-demand viewing using the virtual conference link beginning October 3, 2022 at 4:00 PM EST and will be archived for 120 days: https://wsw.com/webcast/chard14/xcur/1943406

Exicure will be taking 1x1 investor meetings with registered conference attendees.

About Exicure

Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening. For further information, see www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005015/en/

Contacts

Media:
Karen Sharma
MacDougall
781-235-3060
ksharma@macdougall.bio